Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease

Circulation

Volumn 97, Issue 2, 1998, Pages 138-141

  Moustapha, Ali ^a   Naso, Arabi ^a   Nahlawi, Maher ^a   Gupta, Anjan ^a,b   Arheart, Kristopher L ^a   Jacobsen, Donald W ^a   Robinson, Killian ^a   Dennis, Vincent W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b AURORA SINAI MEDICAL CENTER   (United States)

Author keywords

Artherosclerosis; Homocysteine; Kidney; Risk factors; Thrombosis

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0031914677     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.2.138     Document Type: Article

References (19)

1. US Renal Data System, USRDS. Annual Data Report; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, April 1996, 1996.
2. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P. Hyperhomocysteinaemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993;43(suppl 41):S72-S77.
3. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121-125.
4. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743-2748.
5. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate levels in healthy subjects. Clin Chem. 1994;40: 873-881.
6. Ueland PM, Refsum H, Brattitröm L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
7. Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
9. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
10. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol E, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
11. Shemin D, Bostom AG, Verhoef P, Nadeau M, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Total plasma homocysteine (tHCY) levels and mortality in dialysis patients. J Am Soc Nephrol. 1996;7:1464. Abstract.
12. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77: 1370-1376.
13. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5-7.
14. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
15. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
16. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation. 1997;95:1119-1121.
17. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephroll. 1993;40:236-240.
18. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism. 1988;37:697-701.
19. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996;49:147-152.